China Resources Pharmaceutical Group Limited
CRPGF
$0.5414
$0.54140.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 35.82B | 35.29B | 34.69B | 34.57B | 34.59B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.82B | 35.29B | 34.69B | 34.57B | 34.59B |
| Cost of Revenue | 30.17B | 29.72B | 29.22B | 29.14B | 29.17B |
| Gross Profit | 5.66B | 5.57B | 5.47B | 5.44B | 5.42B |
| SG&A Expenses | 3.69B | 3.62B | 3.54B | 3.55B | 3.57B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 298.63M | 313.38M | 327.45M | 306.89M | 286.92M |
| Total Operating Expenses | 34.16B | 33.66B | 33.09B | 32.99B | 33.03B |
| Operating Income | 1.67B | 1.63B | 1.60B | 1.58B | 1.57B |
| Income Before Tax | 1.52B | 1.50B | 1.47B | 1.44B | 1.40B |
| Income Tax Expenses | 351.10M | 339.06M | 326.50M | 312.03M | 298.83M |
| Earnings from Continuing Operations | 1.17K | 1.16K | 1.15K | 1.12K | 1.11K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -702.12M | -663.94M | -624.72M | -589.52M | -556.61M |
| Net Income | 465.22M | 494.57M | 523.41M | 534.91M | 549.47M |
| EBIT | 1.67B | 1.63B | 1.60B | 1.58B | 1.57B |
| EBITDA | 2.03B | 2.00B | 1.96B | 1.94B | 1.93B |
| EPS Basic | 0.07 | 0.08 | 0.08 | 0.09 | 0.09 |
| Normalized Basic EPS | 0.05 | 0.06 | 0.06 | 0.06 | 0.06 |
| EPS Diluted | 0.07 | 0.08 | 0.08 | 0.08 | 0.09 |
| Normalized Diluted EPS | 0.05 | 0.06 | 0.06 | 0.06 | 0.06 |
| Average Basic Shares Outstanding | 25.13B | 25.13B | 25.13B | 25.13B | 25.13B |
| Average Diluted Shares Outstanding | 25.13B | 25.13B | 25.13B | 25.13B | 25.13B |
| Dividend Per Share | 0.02 | 0.02 | 0.01 | 0.01 | -- |
| Payout Ratio | 44.60% | 33.35% | 23.25% | 22.75% | 22.15% |